Abstract
A topical microbicide reduces the probability of virus transmission when applied to the vagina or rectum of a person at risk of sexually acquiring HIV-1 infection1,2,3. An effective microbicide could significantly reduce the global spread of HIV-1, particularly if women were able to use it covertly to protect themselves. A microbicide could target the incoming virus and either permanently inactivate it or reduce its infectivity, or it could block receptors on susceptible cells near the sites of transmission1,2,3. We describe here how vaginal administration of the broadly neutralizing human monoclonal antibody b12 can protect macaques from simian-human immunodeficiency virus (SHIV) infection through the vagina. Only 3 of 12 animals receiving 5 mg b12 vaginally in either saline or a gel and then challenged vaginally (up to 2 h later) with SHIV-162P4 became infected. In contrast, infection occurred in 12 of 13 animals given various control agents under similar conditions. Lower amounts of b12 were less effective, suggesting that protection was dose dependent. These observations support the concept that viral entry inhibitors can help prevent the sexual transmission of HIV-1 to humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
van de Wijgert, J. & Coggins, C. Microbicides to prevent heterosexual transmission of HIV: ten years down the road. BETA 15, 23–28 (2002).
Idemyor, V. Promising microbicide approach for prevention of human immunodeficiency virus transmission needs more support. Pharmacotherapy 22, 1074–1076 (2002).
Turpin, J.A. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin. Investig. Drugs 11, 1077–1097 (2002).
Marx, P.A. et al. Progesterone implants enhance SIV vaginal transmission and early virus load. Nat. Med. 2, 1084–1089 (1996).
Harouse, J.M., Gettie, A., Tan, R.C., Blanchard, J. & Cheng-Mayer, C. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 284, 816–819 (1999).
Harouse, J.M. et al. Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIVSF162P3. J. Virol. 75, 1990–1995 (2001).
Shattock, R.J., Griffin, G.E. & Gorodeski, G.I. In vitro models of mucosal HIV transmission. Nat. Med. 6, 607–608 (2000).
Burton, D.R. et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266, 1024–1027 (1994).
Greenhead, P. et al. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J. Virol. 74, 5577–5586 (2000).
Frank, I. & Pope, M. The enigma of dendritic cell-immunodeficiency virus interplay. Curr. Molec. Med. 2, 229–248 (2002).
Parren, P.W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340–8347 (2001).
Hu, J., Gardner, M.B. & Miller, C.J. Simian immunodeficiency virus rapidly penetrates the cervicovaginal mucosa after intravaginal inoculation and infects intraepithelial dendritic cells. J. Virol. 74, 6087–6095 (2000).
Miller, C.J. & Shattock, R.J. Target cells in vaginal HIV transmission. Microbes Infect. (in the press).
Parren, P.W. & Burton, D.R. The antiviral activity of antibodies in vitro and in vivo. Adv. Immunol. 77, 195–262 (2001).
Haase, A.T. The pathogenesis of sexual mucosal transmission and early stages of infection: obstacles and a narrow window of opportunity for prevention. AIDS 15 (suppl. 1), S10–S15 (2001).
Pope, M. et al. Conjugates of dendritic cells and memory T lymphocytes from skin facilitate productive infection with HIV-1. Cell 78, 389–398 (1994).
Sherwood, J.K. et al. Residence half-life of IgG administered topically to the mouse vagina. Biol. Reprod. 54, 264–269 (1996).
Saltzman, W.M., Sherwood, J.K., Adams, D.R., Castle, P. & Haller, P. Long-term vaginal antibody delivery: delivery systems and biodistribution. Biotechnol. Bioeng. 67, 253–264 (2000).
Vernazza, P.L., Eron, J.J., Fiscus, S.A. & Cohen, M.S. Sexual transmission of HIV: infectiousness and prevention. AIDS 13, 155–166 (1999).
Cohen, M.S. et al. Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 349, 1868–1873 (1997).
Chakraborty, H. et al. Viral burden in genital secretions determines male-to-female sexual transmission of HIV-1: a probabilistic empiric model. AIDS 15, 621–627 (2001).
Gupta, P. et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J. Virol. 71, 6271–6275 (1997).
Dyer, J.R. et al. Quantitation of human immunodeficiency virus type 1 RNA in cell free seminal plasma: comparison of NASBA with Amplicor reverse transcription-PCR amplification and correlation with quantitative culture. J. Virol. Meth. 60, 161–70 (1996).
Gray, R.H. et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 357, 1149–1153 (2001).
Burton, D.R. Antibodies, viruses and vaccines. Nat. Rev. Immunol. 2, 706–713 (2002).
Dove, A. Uncorking the biomanufacturing bottleneck. Nat. Biotech. 20, 777–779 (2002).
Acknowledgements
We thank C. Cheng-Mayer and J. Harouse (Aaron Diamond AIDS Research Center, New York) for the SHIV-162P4; R. Maguire and D. Phillips (The Population Council, New York) for the HMC; J. Mascola and M. Lewis for discussing their results from experiments of a similar design; L. Fresh, M. Mefford, A. Hessell, J. LeBlanc, S. Roscoe, R. Rodriguez and M. Paluch for technical assistance; and A. Ammann, M. Wainberg and R. Doms for advice and support. This work was funded by US National Institutes of Health grants AI52048, HD36310, AI49080, RR00164, AI33292, AI52057 and AI40877. M.P. is an Elizabeth Glaser Scientist, supported by the Elizabeth Glaser Pediatric AIDS Foundation. J.P.M. is a Stavros S. Niarchos Scholar. The Department of Microbiology and Immunology at the Weill Medical College gratefully acknowledges the support of the William Randolph Hearst Foundation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
D.B. has financial interests in the antibody b12 through The Scripps Research Institute. If the antibody were commercialized, he would receive some financial remuneration.
Rights and permissions
About this article
Cite this article
Veazey, R., Shattock, R., Pope, M. et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9, 343–346 (2003). https://doi.org/10.1038/nm833
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm833
This article is cited by
-
Mucosal application of the broadly neutralizing antibody 10-1074 protects macaques from cell-associated SHIV vaginal exposure
Nature Communications (2023)
-
Galectins as potential therapeutic targets in STIs in the female genital tract
Nature Reviews Urology (2022)
-
Durable protection against repeated penile exposures to simian-human immunodeficiency virus by broadly neutralizing antibodies
Nature Communications (2020)
-
Plasma concentration of injectable contraceptive correlates with reduced cervicovaginal growth factor expression in South African women
Mucosal Immunology (2020)
-
Antibody-mediated prevention and treatment of HIV-1 infection
Retrovirology (2018)